E1A-Associated p300 Protein
"E1A-Associated p300 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the p300-CBP transcription factors that was originally identified as a binding partner for ADENOVIRUS E1A PROTEINS.
| Descriptor ID |
D050881
|
| MeSH Number(s) |
D08.811.913.050.134.415.500.575.600 D12.776.930.680.600
|
| Concept/Terms |
E1A-Associated p300 Protein- E1A-Associated p300 Protein
- E1A Associated p300 Protein
- p300 Protein, E1A-Associated
- p300 E1A-Associated Coactivator
- E1A-Associated Coactivator, p300
- p300 E1A Associated Coactivator
|
Below are MeSH descriptors whose meaning is more general than "E1A-Associated p300 Protein".
Below are MeSH descriptors whose meaning is more specific than "E1A-Associated p300 Protein".
This graph shows the total number of publications written about "E1A-Associated p300 Protein" by people in this website by year, and whether "E1A-Associated p300 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "E1A-Associated p300 Protein" by people in Profiles.
-
CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer. JCI Insight. 2024 Sep 17; 9(20).
-
Microtubules Sequester Acetylated YAP in the Cytoplasm and Inhibit Heart Regeneration. Circulation. 2025 Jan 07; 151(1):59-75.
-
Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition. Nat Commun. 2024 Apr 25; 15(1):3483.
-
The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. Cardiovasc Res. 2022 05 06; 118(6):1466-1478.
-
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
-
Rubinstein-Taybi syndrome in diverse populations. Am J Med Genet A. 2020 12; 182(12):2939-2950.
-
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes. Mol Cell. 2020 09 03; 79(5):812-823.e4.
-
CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia. 2020 12; 34(12):3269-3285.
-
In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation. Sci Rep. 2020 06 10; 10(1):9389.
-
Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors. Sci Rep. 2020 02 18; 10(1):2851.